Advanced searches left 3/3

Bromocriptine - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 28 July 2022

* If you want to update the article please login/register

Randomized Evaluation of Bromocriptine In Myocardial Recovery THerapy for Peripartum Cardiomyopathy (REBIRTH)

The research will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a controlled trial of bromocriptine therapy to see its effect on myocardial recovery. Within two weeks before consent, all women will have an assessment of LVEF showing an LVEF score of 0 to 0. 35. The participants in the randomized trial will be randomized to standard medical care for heart failure with placebo plus standard or standard therapy plus 8 weeks of bromocriptine. With rivaroxaban 10 mg once daily for 8 weeks, women receiving bromocriptine not currently on anticoagulation will also be undergoing prophylactic anticoagulation. LVEF will be compared to those on standard therapy plus placebo at six months post-inclusion in the women receiving standard therapy plus bromocriptine to those on standard therapy plus placebo. Patients will be followed for up to three years after randomization and survival without heart failure hospitalization will be determined by ethnic group. Breastfeeding is on the rise in prolactin levels, and it's likely that breastfeeding will have a determining role in women with peripartum cardiomyopathy. As bromocriptine does not breastfeed, women who want to continue breastfeeding are excluded from the controlled trial. This report will investigate the effects of bromocriptine therapy on the health of intact 23 kilodalton prolactin and the 16 kDa prolactin fragment, as well as microRNA 146a. The biomarker analysis will also be conducted in the observational group of women who are still breastfeeding due to continued breast feeding.

Source link: https://clinicaltrials.gov/ct2/show/NCT05180773


A Multimodel Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for Type 2 Diabetes

Elevated intake raises body mass and promotes T2DM risk by dysregulation of glucagon-like peptide 1, amylin, and adiponectin, which can also have a negative effect on T2DM treatment options. T2DM testing has shown reward response to food images mediates T2DM monitoring, with use of a pharmaceutical, such as bromocriptine, to support behavioral change. Despite the fact that bromocriptine may have a major effect on T2DM therapy or as a prevention therapy in those that are genetically susceptible, no studies are available that specifically investigate the three medical devices available to determine whether a genetically-informed, personalized T2DM therapy is effective.

Source link: https://clinicaltrials.gov/ct2/show/NCT05405244

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions